Empyrean Capital Partners’s Pfizer PFE Stock Holding History

Empyrean Capital Partners’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-1,475,600	Closed	-$39.2M	–	76
2013 Q2	$39.2M	Buy	+1,475,600	New	+$40.8M	0.91%	35

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Empyrean Capital Partners's PFE Position: Q3 2018 in Review

Empyrean Capital Partners sold out of Pfizer (PFE) in Q3 2018, closing a stake of 1,976,250 shares — an estimated $68M sold.

Empyrean Capital Partners first reported a position in PFE in Q2 2013 and held it in 7 quarters. The position peaked at $99.4M in Q1 2018. 2,257 funds tracked by Wall St. Rank hold PFE as of Q3 2018.

Empyrean Capital Partners reported no remaining Pfizer position as of Q3 2018 after selling out during the quarter.
Empyrean Capital Partners sold 1,976,250 Pfizer shares in Q3 2018, an estimated $68M.
Empyrean Capital Partners first reported a position in Pfizer in Q2 2013 and held it in 7 quarters.
Empyrean Capital Partners's Pfizer position peaked at $99.4M in Q1 2018.
2,257 funds tracked by Wall St. Rank held Pfizer as of Q3 2018.

Based on Empyrean Capital Partners's 13F filing for Q3 2018, filed 14 Nov 2018.